Navigation Links
PacificGMP and USC to Collaborate on Recombinant Protein Development and Manufacturing for Phase 1 Clinical Trial
Date:7/27/2009

ampus three miles northeast of downtown Los Angeles, the school's physicians staff neighboring USC University Hospital, USC Norris Comprehensive Cancer Center and Hospital, and the Los Angeles County+USC Medical Center, one of the largest teaching hospitals in the United States. The Mission of the Keck School of Medicine of USC is to improve the quality of life for individuals and society by promoting health, preventing and curing disease, advancing biomedical research and educating tomorrow's physicians and scientists. For more information on Keck School of Medicine of USC visithttp://www.usc.edu/schools/medicine/index.html.

    Contact:

    Gary Pierce
    Chief Business Officer
    PacificGMP
    858-550-4094

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Leigh Pierce

http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=67271


'/>"/>
SOURCE PacificGMP
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. PacificGMP and LigoCyte Pharmaceuticals Announce cGMP Manufacturing Collaboration
2. PacificGMP and Actinium Pharmaceuticals Announce Agreements for cGMP Antibody Manufacturing and Stability Testing
3. PacificGMP to Merge With Pacific Biopharma Group and Create Innovative US-Compliant cGMP Contract Biomanufacturing Facility in China
4. PacificGMP Announces Agreement with BD Biosciences for Cell Banking and cGMP Antibody Manufacturing
5. DuPont and Arzeda Collaborate to Develop Improved Crops to Increase Productivity
6. Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization
7. Syngenta and Evogene to Collaborate on Soybean Nematode Resistance
8. Exosome Diagnostics and DxS Diagnostic Innovations Collaborate to Develop Blood-Based Tests for Key Cancer Mutations
9. ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imaging
10. ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imagin
11. Lab Manager Magazine and Association of Laboratory Managers (ALMA) Collaborate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... and Dallas, TX, USA (PRWEB) , ... July ... ... innovative nano and microsystems, has appointed Francois Vieillard as Sales & Marketing Director. ... at executive positions, Francois Vieillard will be responsible for reinforcing Tronics’ business development ...
(Date:7/30/2015)... , July 30, 2015   Aratana ... pet therapeutics company focused on the licensing, development ... animals, today announced that its strategic partner VetStem ... dose confirmation study of AT-016, an adipose-derived allogeneic ... the treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... ST. LOUIS, July 30, 2015 ... period in 2014) , Reported sales were $697 ... of 2014.  Sales grew organically by 8%, and changes ... Recent acquisitions increased sales by 1%. , By ... 8% in Applied and 11% in SAFC Commercial. ...
(Date:7/29/2015)... 30, 2015 Sanofi, a ... the second quarter of 2015. CEO Olivier ... its performance in different businesses. Watch ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered in the ... - Performance drivers - Diabetes ...
Breaking Biology Technology:Tronics appoints Francois Vieillard as Sales and Marketing Director 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... Regional Cancer PatientsNEW ORLEANS, April 28 Ochsner Health ... Health Sciences Center , New Orleans ( www.lsuhsc.edu ... the region,s cancer patients by combining clinical care and ... and provide better access to care. This collaboration will ...
... could prove efficacious for both prophylactic and ... Corporation (NYSE AMEX: CVM ) ... that vaccines utilizing its proprietary L.E.A.P.S.(TM) (Ligand ... potentially induce protection against illnesses such as ...
... 28 PharmAthene, Inc. (NYSE Amex: PIP ... and chemical threats, announced today that results from a ... at the 12th Annual Conference on Vaccine Research, being ... is sponsored by the National Foundation of Infectious Diseases.David ...
Cached Biology Technology:Ochsner and LSUHSC Partner to Provide Better Local Access to Comprehensive Cancer Care 2CEL-SCI's L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies 2CEL-SCI's L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies 3PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 2PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 3PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 4PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 5PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 6PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 7
(Date:7/21/2015)... , July 21, 2015 Today, ZTE ... Already received as well as expected revenues in 2015 that relate ... FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... FPC1 02 5 for Axon , ...
(Date:7/13/2015)... Conn. , Jul. 13, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/188684 for ... achieves another new convenient and secure method to ... new, innovative payment methods, introduced with its groundbreaking ...
(Date:7/8/2015)... YORK , July 8, 2015 Summary ... globally, and the fourth most fatal, with a mortality ... The poor prognosis of pancreatic cancer patients has highlighted ... treatment, which is not being met by the current ... an array of products with varying molecule types and ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... UPTON, NY - A study at the U.S. Department of ... "tagged" with a radioactive form of carbon can be used ... estrogen, in the human brain. The research, published in the ... regions of the brain where aromatase is concentrated may be ...
... breakthrough by scientists at the University of Sheffield has shed ... the land over 470 million years ago by forming a ... today (2 November 2010) in Nature Communications , has ... worked together with soil-dwelling fungi to ,green, the Earth in ...
... 2010 CONRAD, leaders in reproductive health and HIV prevention ... Agency for International Development (USAID). The grant will fund ... also prevent HIV and STI infections. USAID ... conducted by the Centre for Programme Research for AIDS in ...
Cached Biology News:PET scans reveal estrogen-producing hotspots in human brain 2Study shows how ancient plants and soil fungi turned the Earth green 2USAID awards $5 million to CONRAD 2
... KLH-conjugated, synthetic peptide corresponding to ... mouse p19ARF. The epitope ... 62-75. Clone 5-C3-1. Quality ... immunoblot. Stability ...
EDG-1 Western blot control Source: Cell Lysate Application: Western Blotting Control...
Complete cell culture media with cytokines...
...
Biology Products: